Company Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers.
Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.
The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.
HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2011 |
| IPO Date | Apr 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 151 |
| CEO | Joern Aldag |
Contact Details
Address: 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 United States | |
| Phone | 0114318906360 |
| Website | hookipapharma.com |
Stock Details
| Ticker Symbol | HOOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001760542 |
| CUSIP Number | 43906K100 |
| ISIN Number | US43906K1007 |
| Employer ID | 81-5395687 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joern Aldag | Chief Executive Officer and Director |
| Dr. Reinhard Kandera Ph.D. | Chief Financial Officer and Director |
| Prof. Rolf M. Zinkernagel M.D., Ph.D. | Co-Founder |
| Andreas Bergthaler | Co-Founder |
| Lukas Flatz | Co-Founder |
| Dr. Roman Necina Ph.D. | Chief Operations Officer |
| Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer |
| Matthew L. S. Beck | Executive Director of Investor Relations |
| Michael Szumera | Executive Director of Communications |
| Dr. Mark Winderlich Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 8-K | Current Report |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 22, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 29, 2024 | 8-K | Current Report |
| Jan 4, 2024 | EFFECT | Notice of Effectiveness |